Summary of Key Facts:
- The COVID-19 mRNA vaccines were authorized for human use without going through complete animal testing on the active ingredients.
- The animal testing data, which we review in detail, shows that the mRNA and lipid nanoparticle (LNP) shell are present in tissues at high concentrations for about 72 hours, consistent with the timing of systemic reactions to vaccination within the first two to three days.
- The lipids used to create the LNP shell likely stay in the body for four to five months due to their long half-life. (pdf)
- Details on animal testing also show elevated adverse event rates, including joint inflammation and early pregnancy loss.
- The regulatory authorities knew about these adverse events found in animals by January 2021. Nevertheless, the products were permitted to go forward in humans, assuming the benefits would outweigh the risks.
- Post-licensure studies on rare adverse events have found evidence of post-vaccination myocarditis, neurological issues, thrombocytopenia (low platelet counts), and clotting, and a new study shows a strong, twofold increased risk of vision loss.
False Reassurances From CDC
As discussed in Part 1, the U.S. Food and Drug Administration (FDA) did not require Pfizer and Moderna to do biodistribution testing on the active mRNA encoding spike protein used in the vaccines. The FDA’s relaxed biodistribution and pharmacokinetic testing essentially approved a “bioengineered egg” based on an examination of the shell only; in other words, the contents were not tested.Reports provided by Pfizer to the FDA (pdf), Australian, and Japanese (pdf) health authorities, as well as the European Medicines Agency (EMA) (pdf) in January 2021 include identical animal data showing how the new lipid nanoparticle (LNP) shell travels throughout the body. The reports also show how a substitute (“fake”) mRNA (encoding for luciferase) was used to visualize where the mRNA travels.